Key findings towards optimising adalimumab treatment: The concentration-effect curve

Annals of the Rheumatic Diseases

Volumn 74, Issue 3, 2015, Pages 513-518

  Pouw, Mieke F ^a,b   Krieckaert, Charlotte L ^a   Nurmohamed, Michael T ^a   Van Der Kleij, Desiree ^c   Aarden, Lucien ^b   Rispens, Theo ^b   Wolbink, Gertjan ^a,b  

^a Jan Van Breemen Research Institute/Reade   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c Sanquin Diagnostiek   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; AGED; ARTHRITIS, RHEUMATOID; BLOOD; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; DRUG MONITORING; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84922358720     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204172     Document Type: Article

References (29)

1. 2012 EvaluatePharma Ltd., World Preview. 2018. http://www.evaluategroup.com/Public/EvaluatePharma-World-Preview-2018-Embracing-the-Patent-Cliff.aspx (accessed 23 Mar 2013).
2. Adalimumab Product Approval Information-Licensing Action 12/31/02. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080610.htm (accessed 28 Mar 2013).
3. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7. Ann Rheum Dis 1999; 58:(Suppl I):I70-2.
4. Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor α monoclonal antibody. Ann Rheum Dis 2000; 59(suppl I):i44-5.
5. Den Broeder A, van de Putte L, Rau R. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002; 29:2288-98.
6. Weisman MH, Moreland LW, Furst D.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25:1700-21.
7. Weinblatt ME, Keystone EC, Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate, The ARMADA trial. Arthritis Rheum 2003; 48:35-45.
8. HumiraTM (adalimumab) patient information. Abbott Laboratories, North Chicago, IL; January 2003.
9. Bartelds GM, Wijbrandts CA, Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66:921-6.
10. Bartelds GM, Krieckaert CL, Nurmohamed MT. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305:1460-8.
11. Guidance for Industry; Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), April 2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf (accessed 23 May 2013).
12. Guidance for Industry, Population Pharmacokinetics, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), February 1999. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf (accessed 23 May 2013).
13. Van Schouwenburg PA, Bartelds GM, Hart M.H., et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010; 362:82-8.
14. Van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72:104-9.
15. Van Schouwenburg PA, Krieckaert CL, Rispens T, et al. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013; 72: 1680-6.
16. Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9:164-72.
17. Van Kuijk AW, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010; 69:624-5.
18. Lecluse LL, Driessen RJ, Spuls P.I., et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146:127-32.
19. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012; 71:1914-15.
20. Bartelds GM, Wijbrandts CA, Nurmohamed M.T., et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010; 69:817-21.
21. Bartelds GM, de Groot E, Nurmohamed MT, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther 2010; 12:R221.
22. Van Schouwenburg PA, Krieckaert CL, Nurmohamed M, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol 2012; 32:1000-6.
23. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38:44-8.
24. Van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999; 26:705-11.
25. ICH Expert Working Group. "Validation of analytical procedures: Text and methodology, Q2(R1)", Current Step 4 version, November 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q2-R1/Step4/Q2-R1-Guideline.pdf (accessed 23 May 2013).
26. Food and Drug Administration (FDA). Guidance for industry: bioanalytical method validation. Rockville, MD: US Food and Drug Administration, 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf (accessed 23 May 2013).
27. Den Broeder AA, Creemers MC, van Gestel AM, et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology 2002; 41:638-42.
28. Chen J, Veras MM, Liu C, et al. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013; (2):CD004524.
29. Vande Casteele N, Gils A, Compernolle G., et al. Overview of the optimization phase of the randomized controlled Trough Level Adapted Infliximab Treatment (TAXIT) trial. In doctoral thesis in pharmaceutical sciences: Vande Casteele N, Optimising anti-tumour necrosis factor therapy in inflammatory bowel disease patients, a step towards personalised dosing. Leuven, Belgium, 2013:87-105.